Milciclib maleate - Nerviano Medical Sciences

Drug Profile

Milciclib maleate - Nerviano Medical Sciences

Alternative Names: PHA 848125C; PHA-125; PHA-848125; PHA-848125AC; TZLS-201

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Tiziana Life Sciences
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Piperazines; Pyrazolones; Quinazolines; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatocellular carcinoma; Thymoma
  • Phase I/II Glioma
  • Phase I Solid tumours
  • Preclinical Liver cancer
  • No development reported Mesothelioma

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 31 Jul 2017 Chemical structure information added
  • 19 Jul 2017 Tiziana Life Sciences plans a phase IIb trial for Hepatocellular carcinoma (Combination therapy)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top